IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Borderline Resectable Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institutemonoclonal_antibodyPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Borderline Resectable Pancreatic Ductal Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cobimetinib University Health Network, Toronto | Phase 2 | B |
Ligritinib Jonsson Comprehensive Cancer Center | Phase 1 | CC |
Zimberelimab Jonsson Comprehensive Cancer Center | Phase 1 | CC |
azd5305 OHSU Knight Cancer Institute | Early Phase 1 | C |
Zn-C3 OHSU Knight Cancer Institute | Early Phase 1 | C |
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) OHSU Knight Cancer Institute | Early Phase 1 | C |
Same molecule, other indications
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →